Amarantus Selected by People's Bank of China for Anhui SME Cross-Border Investment and Trade Cooperation Conference
November 13 2015 - 8:30AM
Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology
company developing therapeutic and diagnostic product candidates in
orphan indications and neurology, announced that the Company has
been selected by the People's Bank of China (PBOC) and Anhui
Province government to participate in the Anhui SME Cross-border
Investment and Trade Cooperation Conference (CITCC) being held on
December 9-10, 2015, in Hefei City Anhui Province, China.
During this time, Amarantus executives will participate in
high-level meetings with key officials, investors and potential
strategic partners from China, focusing on global expansion
opportunities for the Company’s therapeutics pipeline, specifically
its Engineered Skin Substitute (ESS) program as a treatment for
severe burns, as well as applications for its proprietary
Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF).
Hosted by the PBOC and Anhui Province government, the conference
provides a prominent platform to connect SMEs from the world’s
largest economies to build cross-border partnerships and explore
the possibilities of future joint ventures. Over 800 high-profile
participants from the public and private sectors, including
government officials, CEOs and top executives, will gather to
discuss current local market trends of their respective industry
and spark strategic ideas on future development through exclusive
information exchanges. The event also features a distinguished
panel of prominent figures, speaking about important SME
development related issues.
“In light of the recent tragedies in Shangdong and Tianjin where
explosions killed and severely injured hundreds of people, there is
a pressing need for a game-changing wound care product such as ESS
in China where growth and expansion will undoubtedly be coupled
with construction and manufacturing-related accidents that will
likely continue to have a devastating impact,” said Gerald E.
Commissiong, President & CEO of Amarantus.
About the Anhui SME Cross-border
Investment and Trade Cooperation Conference
The Small and Medium-sized Enterprises (SME) Cross-border
Investment and Trade Cooperation Conference (CITCC) provides a
prominent stage for SMEs from the world’s largest economies to
build cross-border partnerships by traveling to Hefei City where
prospective partners meet and see for themselves the possibilities
of a future joint venture. It echoes a measurable surge of Chinese
investments outside of China in recent years, both in magnitude and
diversity, and is also called for as cross-border dynamism between
SMEs in and out of China is picking up steam. At the center of live
interaction, SMEs will meet and establish long-lasting cooperation
with potential Chinese partners, based on successful video pairing
beforehand.
About Amarantus BioScience Holdings, Inc.
Amarantus BioScience Holdings (OTCQX:AMBS) is a biotechnology
company developing treatments and diagnostics for diseases in the
areas of neurology and orphan diseases. The Company has an
exclusive worldwide license to intellectual property rights
associated to Engineered Skin Substitute (ESS), an orphan drug
designated autologous full thickness skin replacement product in
development for the treatment of adult severe burns currently
preparing to enter Phase 2 clinical studies. The Company is
currently evaluating human clinical data from previously conducted
studies in pediatric severe burns and Congenital Giant Hairy Nevus
to support clinical development expansion into those areas.
AMBS also has development rights to eltoprazine, a small molecule
currently in a Phase 2b clinical program for Parkinson's disease
levodopa-induced dyskinesia with the potential to expand into adult
ADHD and Alzheimer's aggression. AMBS owns the intellectual
property rights to a therapeutic protein known as
mesencephalic-astrocyte-derived neurotrophic factor (MANF) and is
developing MANF as a treatment for orphan ophthalmic disorders,
initially in retinitis pigmentosa (RP) and retinal artery occlusion
(RAO). AMBS also owns the discovery of neurotrophic factors
(PhenoGuard™) that led to MANF's discovery.
AMBS' Diagnostics division owns the rights to MSPrecise®, a
proprietary next-generation DNA sequencing (NGS) assay for the
identification of patients with relapsing-remitting multiple
sclerosis (RRMS) at first clinical presentation, has an exclusive
worldwide license to the Lymphocyte Proliferation test (LymPro
Test®) for Alzheimer's disease, which was developed by Prof. Thomas
Arendt, Ph.D., from the University of Leipzig, and owns
intellectual property for the diagnosis of Parkinson's disease
(NuroPro).
For further information please visit www.Amarantus.com, or
connect with the Company on Facebook, LinkedIn, Twitter and
Google+.
Forward-Looking Statements
Certain statements, other than purely historical information,
including estimates, projections, statements relating to our
business plans, objectives, and expected operating results, and the
assumptions upon which those statements are based, are
forward-looking statements. These forward-looking statements
generally are identified by the words "believes," "project,"
"expects," "anticipates," "estimates," "intends," "strategy,"
"plan," "may," "will," "would," "will be," "will continue," "will
likely result," and similar expressions. Forward-looking statements
are based on current expectations and assumptions that are subject
to risks and uncertainties which may cause actual results to differ
materially from the forward-looking statements. Our ability to
predict results or the actual effect of future plans or strategies
is inherently uncertain. Factors which could have a material
adverse effect on our operations and future prospects on a
consolidated basis include, but are not limited to: changes in
economic conditions, legislative/regulatory changes, availability
of capital, interest rates, competition, and generally accepted
accounting principles. These risks and uncertainties should also be
considered in evaluating forward-looking statements and undue
reliance should not be placed on such statements.
Investor and Media Contact:
Ascendant Partners, LLC
Fred Sommer
732-410-9810
fred@ascendantpartnersllc.com
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Apr 2023 to Apr 2024